<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587467</url>
  </required_header>
  <id_info>
    <org_study_id>2018001</org_study_id>
    <nct_id>NCT03587467</nct_id>
  </id_info>
  <brief_title>Study on Gut Microbiota in Chronic HBV Infected Patients</brief_title>
  <acronym>HBV</acronym>
  <official_title>Study on Gut Microbiota in Chronic Hepatitis B Virus Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongshan Hospital Xiamen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongshan Hospital Xiamen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis B Virus(HBV) infection is a common infectious disease affecting up to 2 billion&#xD;
      people worldwide. Around 650 thousand people died of liver failure, cirrhosis and primary&#xD;
      liver cancer caused by chronic hepatitis B every year. Age is the main factor affecting the&#xD;
      chronicity of hepatitis B, while 90% and 25% to 30% of hepatitis b virus(HBV) infection in&#xD;
      perinatal and infant period will develop into chronic infection respectively. Whereas the&#xD;
      proportion in patients above 5 years old is only 5% to 10%. Intestinal microbiota plays an&#xD;
      important role in maintaining nomal physiological function of the intestine and the immune&#xD;
      function of the body. It has been found that the disorder of intestinal microbiota is&#xD;
      associated with numerous intestinal and parenteral diseases. Recently, the relationship&#xD;
      between immune response and intestinal microbiota has been claimed. In a previous study using&#xD;
      IMT to treat HBeAg positive chronic hepatits B patients combined with antiviral theraopy, 80%&#xD;
      of them has reached HBeAg clearance. Increasing evidence suggests that the gut microbiota has&#xD;
      evolved as a new important player in the pathogenesis of hepatitis B virus-induced chronic&#xD;
      liver disease. However, the composition and structure alteration of the gut microbiota&#xD;
      associated with the stage and progression of HBV infection remains unknown. Hence, we&#xD;
      proposed a trial to detected gut microbiota of chronic HBV infected patients high-throughput&#xD;
      16S rRNA gene sequencing to elucidate the microbial influence which contribute to the&#xD;
      microbial shift of patient in different stage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gut microbiota</measure>
    <time_frame>1day</time_frame>
    <description>detected gut microbiota of participants through high-throughput 16S rRNA gene sequencing to elucidate the microbial influence which contribute to the microbial shift of patient in different stage.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Chronic Hepatitis B Infection</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>health</arm_group_label>
    <description>Alcohol free history or alcohol consumption &lt;140g per week in male, &lt;70g per week in female&#xD;
smooth and soft stool like sausage or snake&#xD;
Voluntary participate in this study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chronic hepatitis b carrier</arm_group_label>
    <description>Alcohol free history or alcohol consumption &lt;140g per week in male, &lt;70g per week in female&#xD;
Meet diagnostic criteria of chronic HBV infection in &quot;EASL 2017 Clinical Practice Guidelines on the management&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chronic hepatitis b</arm_group_label>
    <description>Alcohol free history or alcohol consumption &lt;140g per week in male, &lt;70g per week in female&#xD;
Meet diagnostic criteria of chronic hepatitis B in &quot;EASL 2017 Clinical Practice Guidelines on the management&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>decompensated cirrhosis</arm_group_label>
    <description>Alcohol free history or alcohol consumption &lt;140g per week in male, &lt;70g per week in female&#xD;
Meet diagnostic criteria of chronic hepatitis B in &quot;EASL 2017 Clinical Practice Guidelines on the management&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>collect fecal specimens</intervention_name>
    <description>collect fresh fecal specimens of participants</description>
    <arm_group_label>chronic hepatitis b</arm_group_label>
    <arm_group_label>chronic hepatitis b carrier</arm_group_label>
    <arm_group_label>decompensated cirrhosis</arm_group_label>
    <arm_group_label>health</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        chronic hepatitis b virus infected&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Alcohol free history or alcohol consumption &lt;140g per week in male, &lt;70g per week in&#xD;
             female&#xD;
&#xD;
          2. smooth and soft stool like sausage or snake&#xD;
&#xD;
          3. Voluntary participate in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Syptom of digestive system disorder such as hematochezia, constipation, Abdominal&#xD;
             distention, abdominal pain, diarrhea and jaundice within 1 month&#xD;
&#xD;
          2. Abormal results of several tests including: fecal routine, fecal occult blood test&#xD;
&#xD;
          3. Be diagnosed as enteritis within 1 month&#xD;
&#xD;
          4. Chronic obstructive pulmonary disease, renal insufficiency and other systemic&#xD;
             diseases.&#xD;
&#xD;
          5. Autoimmune disease&#xD;
&#xD;
          6. Chronic fatigue syndrome and neuropsychic disease&#xD;
&#xD;
          7. A history of antibiotics, microecological preparation, gastrointestinal motility&#xD;
             medicine, laxative, weight loss drug, Glucose lowering, blood fat regulation,&#xD;
             glucocorticoid or immunosuppressor treatment within 1 month&#xD;
&#xD;
          8. History of organic diseases in digestive system such as gastrointestinal polyposis,&#xD;
             ulcers, malignancies, etc.&#xD;
&#xD;
          9. History of gastrointestinal surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhongshan Hospital Affiliated to Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongzhi Xu</last_name>
      <phone>+8613606000360</phone>
      <email>xuhongzhi07@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yurou Xie</last_name>
      <phone>+8618559620899</phone>
      <email>350951378@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>July 3, 2018</last_update_submitted>
  <last_update_submitted_qc>July 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

